Positive Larotrectinib Data for TRK Fusion Cancer Presented at ESMO
September 29th 2019At the ESMO Congress 2019, Ulrik Lassen, MD, PhD, professor of oncology at the University of Copenhagen, discussed the newly-released clinical data highlighting new overall survival and progression-free survival results for larotrectinib (Vitrakvi, Bayer) in tropomyosin receptor kinase (TRK) fusion cancer.
Pharmacy Week in Review: Pinterest Tackles Anti-Vaccine Movement, CLL Linked to Higher Melanoma Risk
September 6th 2019This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.